Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting

Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting

<h3>Background </h3><p dir="ltr">Priming with two doses of AZD1222 (Oxford-AstraZeneca; ChAd) followed by a third mRNA vaccine boosting is considered in several countries, yet comparisons between heterologous and homologous booster efficacy remain unexplored. </p>&l...

Full description

Saved in:
Bibliographic Details
Main Author: Salma Younes (6424865) (author)
Other Authors: Eleonora Nicolai (496034) (author), Nadin Younes (4863280) (author), Massimo Pieri (5023022) (author), Sergio Bernardini (504056) (author), Parveen B. Nizamuddin (14590613) (author), Duaa W. Al-Sadeq (10976754) (author), Hanin I. Daas (17863886) (author), Ahmed Ismail (2671822) (author), Hadi M. Yassine (4675846) (author), Laith J. Abu-Raddad (9262524) (author), Gheyath K. Nasrallah (9200525) (author)
Published: 2024
Subjects:
Biomedical and clinical sciences
Clinical sciences
Immunology
Health sciences
Public health
AZD1222 (Oxford-AstraZeneca, ChAd)
Homologous
Heterologousm
RNA vaccination
Neutralizing antibody
Anti-S1 IgA
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items